Comparison between Corona Remedies IPO and NSDL IPO.
Corona Remedies IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while NSDL IPO is a Mainboard Bookbuilding proposed to list at BSE.
The total issue size of Corona Remedies IPO is up to ₹655.37 Cr whereas the issue size of the NSDL IPO is up to ₹4,010.95 Cr. The final issue price of Corona Remedies IPO is ₹1,062.00 per share and of NSDL IPO is ₹800.00 per share.
| Corona Remedies IPO | NSDL IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹2 per share |
| Issue Price (Lower) | ₹1,008.00 per share | ₹760.00 per share |
| Issue Price (Upper) | ₹1,062.00 per share | ₹800.00 per share |
| Issue Price (Final) | ₹1,062.00 per share | ₹800.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ₹54.00 per share | ₹76.00 per share |
| Market Lot Size | 14 shares | 18 shares |
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 61,74,051 shares | 5,01,45,001 shares |
| OFS Issue Size (Amount) | up to ₹655.37 Cr | up to ₹4,010.95 Cr |
| Issue Size Total | 61,74,051 shares | 5,01,45,001 shares |
| Issue Size Total (Amount) | up to ₹655.37 Cr | up to ₹4,010.95 Cr |
Corona Remedies IPO opens on Dec 08, 2025, while NSDL IPO opens on Jul 30, 2025. The closing date of Corona Remedies IPO and NSDL IPO is Dec 10, 2025, and Aug 01, 2025, respectively.
| Corona Remedies IPO | NSDL IPO | |
|---|---|---|
| Anchor Bid Date | Dec 05, 2025 | Jul 29, 2025 |
| Issue Open | Dec 08, 2025 | Jul 30, 2025 |
| Issue Close | Dec 10, 2025 | Aug 01, 2025 |
| Basis Of Allotment (Tentative) | Dec 11, 2025 | Aug 04, 2025 |
| Initiation of Refunds (Tentative) | Dec 12, 2025 | Aug 05, 2025 |
| Credit of Share (Tentative) | Dec 12, 2025 | Aug 05, 2025 |
| Listing date (Tentative) | Dec 15, 2025 | Aug 06, 2025 |
| Anchor Lockin End date 1 | Jan 09, 2026 | Sep 02, 2025 |
| Anchor Lockin End date 2 | Mar 10, 2026 | Nov 01, 2025 |
Corona Remedies IPO P/E ratio is 43.47, as compared to NSDL IPO P/E ratio of 46.63.
| Corona Remedies IPO | NSDL IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Corona Remedies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 65% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)National Securities Depository Ltd.'s revenue increased by 12% and profit after tax (PAT) rose by 25% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 72.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 69 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 43.47 | 46.63 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹6495.20 Cr. | ₹16000.00 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 27.50% | 17.11% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 41.32% | 22.7% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹24.43 | ₹17.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 24.65% | 17.11% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Corona Remedies IPO Retail Individual Investors (RII) are offered 21,40,606 shares while in NSDL IPO retail investors are offered 21,40,606 shares. Qualified Institutional Buyers (QIB) are offered 12,23,203 shares in Corona Remedies IPO and 1,00,12,000 shares in NSDL IPO.
| Corona Remedies IPO | NSDL IPO | |
|---|---|---|
| Anchor Investor Reservation | 18,34,804 shares | 1,50,17,999 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 12,23,203 shares | 1,00,12,000 shares |
| NII | 9,17,403 shares | 75,09,001 shares |
| RII | 21,40,606 shares | 1,75,21,001 shares |
| Employee | 58,035 shares | 85,000 shares |
| Others | ||
| Total | 61,74,051 shares | 5,01,45,001 shares |
Corona Remedies IPO subscribed 144.54x in total, whereas NSDL IPO subscribed 41.02x.
| Corona Remedies IPO | NSDL IPO | |
|---|---|---|
| QIB (times) | 293.80x | 103.97x |
| NII (times) | 220.18x | 34.98x |
| Big NII (times) | 246.67x | 37.73x |
| Small NII (times) | 167.20x | 29.47x |
| RII (times) | 30.39x | 7.76x |
| Employee (times) | 15.56x | 15.39x |
| Other (times) | ||
| Total (times) | 144.54x | 41.02x |
